The Future of Medicine will be the Medicine of Frequencies

-Albert Einstein




Tedence
Frequency Medicine
The Future of Medicine

Mission

- Revolutionizing Healthcare by AI-Driven Frequency Medicine

Validation and Partnerships

- JDRF Israel– First Place Winner 2023 Innovation Challenge
- IIA Tnufa- Peer reviewed Israeli Government award
  - Facilitates future IIA non-dilutive matching funding
- Expand Space Accelerator- Artemis/Nasa/Space IL
- Hadassah Medical Center- Ongoing POC Clinical Trial
- Partnership with TDK- Novel ELF-EMF sensors
- Evolution Inc – Proprietary real-time algorithm
- Zeron/Taga- Initial wearable prototype design completed

SPACEIL NASA JDRF IMPROVING LIVES. CURING TYPE 1 DIABETES.

ARTEMIS רשות החדשנות Israel Innovation Authority

TDK Hadassah University Hospital

evolution zeron taga



What we can’t measure
we can’t study
and we can’t treat

Unlocking the future requires a
technological breakthrough



When unprecedented 21st century computing software meets unprecedented 21st century sensory hardware

The future of medicine begins to form

Cells speak EMF.

And now we're part of the conversation.

This dialogue will save lives.



As cells work electrically, they produce electromagnetic fields (EMFs) while performing tasks.

Our sensors and proprietary AI interprets these signals to form the basis for EMF based diagnosis and treatment

Different Diseases. Different EMF Signatures.

Diabetes

Epilepsy

Cancer



<u>What we're doing in 3 lines</u>

First **identify** a diseases' unique EMF signature

Then **monitor** for that signature to **predict** future episodes

Finally, **treat** the disease by **emitting** EMF based on diagnostic measurements

Tedence is introducing a new measurable vital signal to humanity– the EMF.

Diabetes

Market Size
In the US Only

$438B

in 2030



Cancer

Market Size
In the US Only

$240B

in 2030

Epilepsy

Market Size
In the US Only

$15.1B

in 2030

We are moving forward with **Diabetes** due to the **Fast** and **Transparent** results that can be **Ethically Controlled**.

Our first prototype will warn type-1 diabetics about impending low blood sugar - a potentially deadly event.

Diabetes Diagnostics & Therapeutics Goods and Services in The USA Only

$7 B
by 2030
SOM

$59 B
by 2030
SAM

$438 B
by 2030
TAM

Massive market opportunity

Diabetes is the defining disease of the 21st century.
With 1 in 3 Americans born today will get diabetes.

EMF Changes Precedes Glycemic Events



- Rise in EMF begins following insulin administration (without eating)
- Max rise in EMF precedes hypoglycemic event by 40 minutes
- Decrease in EMF directly related to food intake (without insulin coverage) and low EMF precedes hyperglycemic event by 35 minutes

Measuring Mitochondrial Activity

Impending Hypoglycemia

- Increased mitochondrial activity https://doi.org/10.3390/ijms222413470
- Increased electrical activity
- Threshold at maximal signal is a Positive number
- Data consistent with increased electrical activity

Impending Hyperglycemia

- Decreased mitochondrial activity https://journals.physiology.org/doi/full/10.1152/ajpendo.00332.2004
- Decreased electrical activity
- Threshold at maximal signal is a Negative number
- Data consistent with decreased electrical activity

T1D Pilot POC Trial at Hadassah Ein Kerem- Ongoing

Trial Begun January 2025

PI: Prof Gil Leibovitz- Head of Diabetes Unit

20 Study Subjects:

10 T1DM with Insulin Clamp to simulate glycemic events

10 Normal Healthy Subjects

the current market solutions still fall short...

Invasive diabetes treatments such as insulin pumps and Continuous Glucose Monitors (CGMs) can delay treatment or cause severe hypoglycemia and hyperglycemia.

Insulin injections or medications fail to treat diabetes because underlying cellular dysfunctions are left unaddressed.

~90% of diabetics don't use CGMs

Invasive

Painful

Cumbersome

Expensive

Inaccurate

Uncomfortable

Tedence Solves for All of That.



Robert Gabbay
MD, PhD CSO CMO

American Diabetes Association.
Connected for Life.

"Providing 15-30 minute alert for impending hypoglycemia is extremely important for prevention and currently stands as an unmet medical need"

"Ensuring an early warning system for oncoming low blood sugar is vital for prevention and fulfills a critical medical necessity."

Prof Moshe Philip
Director of the Institute of Endocrinology and Diabetes, the National Center for Juvenile Diabetes

מרכז שניידר לרפואת ילדים בישראל
مركز شنايدر لطب الأطفال في إسرائيل
Schneider Children's Medical Center of Israel



The future will be as simple as a wearable

- Real-Time Predictive Monitoring with 15-60 minutes advance warning.
- ELF-EMF Theranostic Platform: Non-invasive, needle-free, and drug-free.
- Enhanced patient comfort and convenience with first-mover advantage in a new paradigm of diabetes management.

Business Model
Revenue generation strategy

Subscriptions

for early warnings module complementing CGM systems.



Value

working with payers, employers, and insurance companies.

Rollout

Rollout as a De Novo adjunct device in 2 years.

“A Subscription for Life”

Revenue Streams and Exit Scenarios

Brand Building: B2C

1) Sales of Tedence brand Device+SaaS to:
   a) retail consumers
   b) partner with insurance companies
2) Joint Venture with leading tech corps to sell Tedence brand device+SaaS through their sales channels.

Licensing: B2B2C

1) Licensing SaaS to leading tech corps (“Applewatch powered by Tedence”)
2) Medical device companies, ie:
   a) nursing homes for bed monitoring
   b) adjunct use with CGMs and insulin pump companies
3) Joint Venture with leading tech corporations to sell Tedence tech under their brand

2025 Milestones

1) T1D Diagnostic Pilot Trial
2) Development of Wearable Diagnostic Prototype
3) T1D Theranostic Proof of Concept Trial
4) Breast Cancer Proof of Concept Trial

Exit

1) M&A by multinational technology corporation
2) IPO
3) Stay Private with Strong Cash Flow

Two Step Solution

Diagnostic

- 24/7 Non-Invasive Monitoring
- FDA DeNovo Approval 2027

Full Theranostic

- FT Non-Invasive Disease Mgmt
- Full FDA Approval 2029

Exceptional returns for unlocking humanity's next generation of medicine



Generating Revenue by 2027

PNL	2025	2026	2027	2028	2029	2030	2031
Total Net Revenue	$0	$0	$ 7,802,130	$ 138,371,202	$ 1,078,126,083	$ 6,887,915,544	$ 16,723,797,162
Gross Profit	$ -	$ -	$ 5,682,484	$ 100,588,436	$ 805,049,622	$ 5,222,310,502	$ 12,688,651,517
Gross Profit Margin			**72.83%**	**72.69%**	**74.67%**	**75.82%**	**75.87%**
Operating Income				$ 86,661,358	$ 765,985,531	$ 5,148,826,612	$ 12,541,844,800
EBITDA Margin				**62.63%**	**71.05%**	**74.75%**	**74.99%**
Net Income				$ 62,686,011	$ 586,786,511	$ 3,959,453,883	$ 9,647,561,202
Net Profit Margin				**45.30%**	**54.43%**	**57.48%**	**57.69%**

2025 Fundraising

Seeking

$300k

Tranche A:

- Raising: SAFE round of $300k
  - private funds win the IIA boost (submit a 2.5M NIS budget, IIA pays 1.5M NIS and private investors pay 1M NIS. 1M NIS=$275k, extra $25k for overhead)
- Funds used to build wireless device prototype.
- Deadline to get in is March 15th 2025

Tranche B:

- Raise $2.7M after T1D pilot data gathered
  - private funds win the IIA seed grant (submit a 15M NIS budget, IIA pays 5.0M NIS and private investors pay 10M NIS. 10M NIS=$2.7M)
- Funds used to conduct T1D pivot trials, T2D pilot trial, Epilepsy pilot trial and Theranostic Proof of Concept

Roadmap to the Future of Medicine



2025 Milestones

1) T1D Diagnostic Pilot Trial
2) Development of Wearable Diagnostic Prototype
3) T1D Theranostic Proof of Concept Trial
4) Breast Cancer Proof of Concept Trial

Experience Leadership

Morris Laster, MD
CEO

6X Founder & CEO of companies that IPO'd on NASDAQ, AIM, and TASE. 30+ years of industry experience in biomedical innovations.

Prof. Pavel Ginzburg
CSO

Professor of Electrical Engineering with expertise in radio waves, devices, solid-state physics, optics, and nanoplasmonics.

Noah Pickholtz
COO

10+ years of IR sales and ops, former CRO of BridgeWise, $100M+ in fundraising experience, MBA from Bar-Ilan University.

Moshe Kelner
CBDO

30+ years of business development, former CEO of Advanced Mem-Tech, MBA from Hebrew University.

Strategic Advisory Board

Doctor
William Levine

Founder of Izun Pharmaceuticals and CannRx, pioneering plant-based therapeutics and pharmaceutical innovation.

Prof.
Yosi Shacham

Leading researcher in micro- and nano-electronics, solid-state physics, and quantum mechanics.

Prof.
Pavel Ginzburg

Professor of Electrical Engineering with expertise in radio waves, devices, solid-state physics, optics, and nanoplasmonics.

Prof.
Johnjoe McFadden

Professor of Molecular Genetics, known for the conscious electromagnetic information (cemi) field theory.

Prof.
Dirk KF Meijr

Professor Emeritus of Pharmacokinetics & Pharmacotherapy, co-author of 630 scientific publications.

Be Part of the Greatest Medical Breakthrough of Our Time

Let’s talk!

contact information

Dr. Morris Laster: morris@tedence.com
Gideon Meir: gideon@tedence.com

Website
www.tedence.com